Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series

[1]  J. Bernstein,et al.  Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. , 2020, Allergy and asthma proceedings.

[2]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[3]  J. Bernstein,et al.  Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks , 2020, Allergy.

[4]  Todor A Popov,et al.  Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence , 2020, Allergy.

[5]  H. Farkas,et al.  Biological therapy in hereditary angioedema: transformation of a rare disease , 2020, Expert opinion on biological therapy.

[6]  B. Anawalt.  Diagnosis and Management of Anabolic Androgenic Steroid Use. , 2019, The Journal of clinical endocrinology and metabolism.

[7]  H. Farkas.  Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets , 2019, Expert opinion on therapeutic targets.

[8]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[9]  M. Triggiani,et al.  Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema , 2018, The New England journal of medicine.

[10]  J. Ross,et al.  Oxandrolone Treatment Results in an Increased Risk of Gonadarche in Prepubertal Boys With Klinefelter Syndrome , 2018, The Journal of clinical endocrinology and metabolism.

[11]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update , 2018, Allergy.

[12]  S. Lewis,et al.  Data sharing in clinical trials – practical guidance on anonymising trial datasets , 2018, Trials.

[13]  Sahana Kumar,et al.  Stanozolol induced precocious puberty , 2018 .

[14]  Publisher's Note , 2018, Anaesthesia.

[15]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[16]  B. Zuraw,et al.  Tolerability and Effectiveness of 17-α-Alkylated Androgen Therapy for Hereditary Angioedema: A Re-examination. , 2016, The journal of allergy and clinical immunology. In practice.

[17]  S. Lewis,et al.  Data sharing in clinical trials - practical guidance on anonymising trial datasets , 2015, Trials.

[18]  M. Riedl.  Critical appraisal of androgen use in hereditary angioedema: a systematic review. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[19]  M. Riedl,et al.  Current medical management of hereditary angioedema: follow-up survey of US physicians. , 2015, The journal of allergy and clinical immunology. In practice.

[20]  H. Farkas,et al.  Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema , 2014, Orphanet Journal of Rare Diseases.

[21]  R. Wood,et al.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. , 2014, Endocrine reviews.

[22]  J. Bernstein,et al.  Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. , 2014, The journal of allergy and clinical immunology. In practice.

[23]  P. Martus,et al.  Development, validation, and initial results of the Angioedema Activity Score , 2013, Allergy.

[24]  Aasia I. Ghazi,et al.  Hereditary angioedema: epidemiology, management, and role of icatibant , 2013, Biologics : targets & therapy.

[25]  D. Meyer‐Olson,et al.  Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.

[26]  B. Chipps.  Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema , 2011, Pediatrics.

[27]  C. Chrvala,et al.  Current medical management of hereditary angioedema: results from a large survey of US physicians. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[28]  M. Maurer,et al.  Long‐term prophylaxis of hereditary angioedema with androgen derivates: a critical appraisal and potential alternatives , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[29]  B. Zuraw.  The Pathophysiology of Hereditary Angioedema , 2010, The World Allergy Organization journal.

[30]  A. Kaplan,et al.  The bradykinin-forming cascade and its role in hereditary angioedema. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  H. Pope,et al.  Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? , 2008, Drug and alcohol dependence.

[32]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[33]  M. López-Trascasa,et al.  Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. , 2008, The Journal of allergy and clinical immunology.

[34]  K. Scharffetter-Kochanek,et al.  C1‐INH and C3/C4 levels do not correlate with long‐term danazole dosage and HAE‐1 attack‐free interval , 2005, Allergy.

[35]  L. Romics,et al.  Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[36]  M. Gompels,et al.  C1 inhibitor deficiency: consensus document , 2005, Clinical and experimental immunology.

[37]  K. Kragballe,et al.  Hereditary Angioedema. , 2018, The New England journal of medicine.

[38]  G. Chrousos,et al.  Endocrine withdrawal syndromes. , 2003, Endocrine reviews.

[39]  M. Cicardi,et al.  Increased expression of C1-inhibitor mRNA in patients with hereditary angioedema treated with Danazol. , 2003, Immunology letters.

[40]  M. Mędraś,et al.  [Treatment strategies of withdrawal from long-term use of anabolic-androgenic steroids]. , 2001, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[41]  F. Rosen,et al.  A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema , 1998, Transfusion.

[42]  M. Cicardi,et al.  Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. , 1997, The Journal of allergy and clinical immunology.

[43]  F. Rosen,et al.  Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. , 1996, The New England journal of medicine.

[44]  P. Brunskill.  The effects of fetal exposure to danazol , 1992 .

[45]  M. Cicardi,et al.  Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. , 1980, The Journal of allergy and clinical immunology.

[46]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[47]  W. Spaulding,et al.  METHYLTESTOSTERONE THERAPY FOR HEREDITARY EPISODIC EDEMA (HEREDITARY ANGIONEUROTIC EDEMA) , 1960 .